Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions

• US 10,214,770 B2
• Filed: 05/10/2016
• Issued: 02/26/2019
• Est. Priority Date: 05/08/2012
• Status: Active Grant

• Current Assignee: Adaptive Biotechnologies Corp.
• Original Assignee: Adaptive Biotechnologies Corp.
• Inventors: Robins, Harlan Saul, Carlson, Christopher Scott, Livingston, Robert J., Emerson, Ryan O., Sherwood, Anna M.
• Primary Examiner(s): Strzelecka, Teresa E
• Application Number:
  US15/150,753
• Publication Number:
  US 20160319340A1
• Time in Patent Office: 1,022 Days
• CPC Class Codes: C12Q 1/6806 Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay C12Q1/6804 takes precedence
• CPC Class Codes: C12Q 1/6851 Quantitative amplification
• CPC Class Codes: C12Q 1/6881 for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• CPC Class Codes: C12Q 2527/143 Concentration of primer or probe
• CPC Class Codes: C12Q 2537/143 Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
• CPC Class Codes: C12Q 2545/101 with an internal standard/control
• CPC Class Codes: C12Q 2545/113 with an external standard/control, i.e. control reaction is separated from the test/target reaction
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: C12Q 2600/166 Oligonucleotides used as internal standards, controls or normalisation probes

Abstract

Compositions and methods are described for standardizing the DNA amplification efficiencies of a highly heterogeneous set of oligonucleotide primers as may typically be used to amplify a heterogeneous set of DNA templates that contains rearranged lymphoid cell DNA encoding T cell receptors (TCR) or immunoglobulins (IG). The presently disclosed embodiments are useful to overcome undesirable bias in the utilization of a subset of amplification primers, which leads to imprecision in multiplexed high throughput sequencing of amplification products to quantify unique TCR or Ig encoding genomes in a sample. Provided is a composition comprising a diverse plurality of template oligonucleotides in substantially equimolar amounts, for use as a calibration standard for amplification primer sets. Also provided are methods for identifying and correcting biased primer efficiency during amplification.

Claims

1. A method for quantifying a plurality of rearranged nucleic acid molecules encoding one or a plurality of adaptive immune receptors in a biological sample that comprises rearranged nucleic acid molecules from lymphoid cells of a mammalian subject, each adaptive immune receptor comprising a variable (V) region and a joining (J) region, the method comprising:

(A) amplifying nucleic acid molecules in at least one multiplex polymerase chain reaction (PCR) that comprises;

(1) rearranged nucleic acid molecules from the biological sample that comprises lymphoid cells of the mammalian subject,

(2) a composition, comprising a plurality of synthetic template oligonucleotides comprising sequences of rearranged nucleic acid molecules encoding one or more adaptive immune receptors and at least one unique oligonucleotide barcode sequence such that each synthetic template oligonucleotide has a unique oligonucleotide sequence and wherein a known number of each of the plurality of synthetic template oligonucleotides having a unique oligonucleotide sequence is present,

(3) an oligonucleotide amplification primer set comprising;

a plurality of V-segment oligonucleotide primers and a plurality of J-segment oligonucleotide primers, wherein the primer set is capable of promoting amplification in said at least one multiplex polymerase chain reaction (PCR) of

(i) substantially all synthetic template oligonucleotides in the composition to produce a multiplicity of amplified synthetic template oligonucleotides, said multiplicity of amplified synthetic template nucleic acid molecules being sufficient to quantify diversity of the synthetic template oligonucleotides in the composition, and

(ii) substantially all rearranged nucleic acid molecules encoding adaptive immune receptors in the biological sample to produce a multiplicity of amplified rearranged nucleic acid molecules, said multiplicity of amplified rearranged nucleic acid molecules being sufficient to quantify diversity of the rearranged nucleic acid molecules in the nucleic acid from the biological sample,

(B) quantitatively sequencing said amplified synthetic template oligonucleotides and said amplified rearranged nucleic acid molecules to quantify

(i) a synthetic template product number of amplified template oligonucleotides which contain the at least one unique oligonucleotide barcode sequence, and

(ii) a rearranged product number of amplified rearranged nucleic acid molecules which lack a unique oligonucleotide barcode sequence;

(C) calculating an amplification factor by dividing the synthetic template product number of (B)(i) by the known number of each of the plurality of synthetic template oligonucleotides having at least one unique barcode oligonucleotide sequence of (A)(2); and

(D) dividing the rearranged product number of (B)(ii) by the amplification factor calculated in (C) to quantify the number of unique adaptive immune receptor encoding rearranged nucleic acid molecules in the sample.

2. The method of claim 1, wherein the quantified number of unique adaptive immune receptor encoding rearranged nucleic acid molecules in the sample is the number of unique B cell or unique T cell genome templates in the sample.

3. The method of claim 1, wherein each V-segment primer comprises a nucleotide sequence of at least 15 contiguous nucleotides that is complementary to at least one functional adaptive immune receptor V region-encoding gene segment.

4. The method of claim 1, wherein each J-segment primer comprises a nucleotide sequence of at least 15 contiguous nucleotides that is complementary to at least one functional adaptive immune receptor J region-encoding gene segment.

5. The method of claim 1, wherein each amplified nucleic acid molecule in the plurality of amplified synthetic template oligonucleotides and in the plurality of amplified rearranged nucleic acid molecules is less than 1000 nucleotides in length.

6. The method of claim 1, wherein said oligonucleotide amplification primer set does not include oligonucleotide primers that specifically hybridize to a V-region pseudogene or orphon or a J-region pseudogene or orphon.

7. The method of claim 1, wherein said plurality of synthetic template oligonucleotides each comprises an oligonucleotide sequence of the general formula:

5′

-U1-B1-V-B2-R-B3-J-B4-U2-3′

 

 

[I]

wherein;

(a) V is an oligonucleotide sequence comprising at least 20 and not more than 1000 contiguous nucleotides of an adaptive immune receptor variable (V) region encoding gene sequence, or the complement thereof, and each V comprising a unique V-region oligonucleotide sequence;

(b) J is an oligonucleotide sequence comprising at least 15 and not more than 600 contiguous nucleotides of an adaptive immune receptor joining (J) region encoding gene sequence, or the complement thereof, and each J comprising a unique J-region oligonucleotide sequence;

(c) U1 is either nothing or comprises an oligonucleotide sequence that is selected from

(i) a first universal adaptor oligonucleotide sequence and

(ii) a first sequencing platform-specific oligonucleotide sequence that is linked to and positioned 5′

to a first universal adaptor oligonucleotide sequence;

(d) U2 is either nothing or comprises an oligonucleotide sequence that is selected from

(i) a second universal adaptor oligonucleotide sequence, and

(ii) a second sequencing platform-specific oligonucleotide sequence that is linked to and positioned 5′

to a second universal adaptor oligonucleotide sequence;

(e) at least one of B1, B2, B3, and B4 is present and each of B1, B2, B3, and B4 comprises an oligonucleotide comprising a barcode sequence of 3-25 contiguous nucleotides, that uniquely identifies, as a paired combination,

(i) the unique V-region oligonucleotide sequence of (a) and

(ii) the unique J-region oligonucleotide sequence of (b);

(f) R is either nothing or comprises a restriction enzyme recognition site that comprises an oligonucleotide sequence that is absent from (a)-(e); and

(g) one or more unique random polynucleotide sequences positioned between or within components of formula I.

8. The method of claim 7, wherein the one or more unique random polynucleotide sequences each comprises at least 2 contiguous nucleotides.

9. The method of claim 7, wherein the plurality of synthetic template oligonucleotides comprises a number of at least a or at least b unique oligonucleotide sequences, whichever is larger, wherein a is the number of unique adaptive immune receptor V region-encoding gene segments in the subject and b is the number of unique adaptive immune receptor J region-encoding gene segments in the subject, and the composition comprises at least one synthetic template oligonucleotide for each unique V-region oligonucleotide sequence and at least one synthetic template oligonucleotide for each unique J-region oligonucleotide sequence.

10. The method of claim 9, wherein a ranges from 1 to a number of maximum V gene segments in the mammalian genome of the subject.

11. The method of claim 9, wherein b ranges from 1 to a number of maximum J gene segments in the mammalian genome of the subject.

12. The method of claim 9, wherein the plurality of template oligonucleotides comprises at least (a×

b) unique oligonucleotide sequences, where a is the number of unique adaptive immune receptor V region-encoding gene segments in the mammalian subject and b is the number of unique adaptive immune receptor J region-encoding gene segments in the mammalian subject, and the composition comprises at least one template oligonucleotide for every possible combination of a V region-encoding gene segment and a J region-encoding gene segment.

13. The method of claim 7, wherein J comprises an oligonucleotide sequence comprising a constant region of the adaptive immune receptor J region encoding gene sequence.

14. The method of claim 1, wherein the one or more adaptive immune receptors is selected from the group consisting of TCRB, TCRG, TCRA, TCRD, IGH, IGK, and IGL.

15. The method of claim 7, wherein the V oligonucleotide sequence of (a) encodes a TCRB, TCRG, TCRA, TCRD, IGH, IGK, or IGL receptor V-region polypeptide.

16. The method of claim 7, wherein the J oligonucleotide sequence of (b) encodes a TCRB, TCRG, TCRA, TCRD, IGH, IGK, or IGL receptor J-region polypeptide.

17. The method of claim 7, further comprising a stop codon sequence between V and B2.

18. The method of claim 7, wherein V is an oligonucleotide sequence comprising at least 30 contiguous nucleotides of the adaptive immune receptor V region encoding gene sequence, or the complement thereof.

19. The method of claim 7, wherein V is an oligonucleotide sequence comprising not more than 500 contiguous nucleotides of an adaptive immune receptor V region encoding gene sequence, or the complement thereof.

20. The method of claim 7, wherein J is an oligonucleotide sequence comprising at least 16 contiguous nucleotides of an adaptive immune receptor J region encoding gene sequence, or the complement thereof.

21. The method of claim 7, wherein J is an oligonucleotide sequence comprising not more than 500 contiguous nucleotides of an adaptive immune receptor J region encoding gene sequence, or the complement thereof.

22. The method of claim 7, wherein each synthetic template oligonucleotide is less than 1000 nucleotides in length.

23. The method of claim 7, wherein said one or more unique random polynucleotide sequences each comprises at least 2 contiguous nucleotides.